What are the specific functions and effects of acotinib/concostat?

Acalabrutinib is a highly selective second-generation Bruton's tyrosine kinase (BTK) inhibitor. As one of the representative targeted drugs in the field of hematological tumor treatment in recent years, its emergence has filled the shortcomings in long-term drug resistance and side effect management for patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL) and other diseases. The main efficacy of acotinib comes from its unique molecular mechanism. It precisely binds to BTK protein and blocks the B cell receptor (BCR) signaling pathway, thereby inhibiting the proliferation and survival of abnormal B cells and achieving the purpose of controlling tumor development.

Compared with the first-generation BTK inhibitor ibrutinib, acotinib has significant advantages in molecular selectivity. Although ibrutinib pioneered the clinical use of BTK inhibition, its off-target inhibition of other kinases such as EGFR and ITK often leads to adverse events such as arrhythmia, bleeding tendency, and rash. Acotinib has a stronger target specificity and almost completely targets BTK, thus reducing common cardiotoxicity and bleeding-related side effects, allowing patients to receive treatment for a longer period of time without having to frequently discontinue medication or adjust the regimen.

In terms of clinical application, acotinib is not only suitable for newly treated patients, but also for patients who are resistant to or relapsed with other regimens, showing a strong broad spectrum. Additionally, because its side effects are relatively mild, patients' quality of life and compliance are improved. In some long-term follow-up studies, acotinib has shown a trend of durable disease remission rate and reduced risk of disease progression, demonstrating its long-term application value.

Therefore, the role of acotinib can be summarized in three aspects: First, it delays the development ofB cell malignant tumors through precise target inhibition; second, it improves patients' tolerance to treatment and reduces discontinuation due to side effects; third, it expands the treatment options for hematological tumors and provides strong support for precision medicine. Kangcoqi is not only a drug, but also represents the progress in the treatment of hematological tumors from "one size fits all" to targeted and individualized treatment.

Reference materials:https://www.calquence.com/